Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Ron Nairn who wrote (12966)	10/6/2003 1:37:15 AM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

Hi Ron Curious, in the sense that Mr Cloutier and Searle Canada had a lot to do with Arthitis pain and Celebrex. But at first I didn't think AstraZenca had any pain control profile based on an initial look at their internation website. I think I doth speak too soon. From the AstraZeneca Canada website, Pain and Pain Control: R&D Montréal AstraZeneca - a World Leader in Pain Control Chronic pain, which affects millions of North Americans, can critically impact a person's quality of life and general well-being. Moreover, the economic costs are staggering. In North America alone, the direct and indirect costs of severe and chronic pain are substantial, with estimates ranging up to US$90 billion annually. As a leading pharmaceutical company, AstraZeneca is dedicated to the continual development of new medicines to improve the quality of life and increase life expectancy for many patients. The vision of AstraZeneca PLC is to become the leading company in pain control worldwide, both through maintenance and expansion of the firm's leading position in anaesthesia and through the introduction of innovative products that meet the needs in the large and rapidly growing analgesia segment. astrazeneca.ca It appears the writer has buried chronic pain, analgesic and anaesthesia all together. Perhaps for brevity. But this is the connection to Mr Cloutier, so I am no longer "curious". :-) From AstraZeneca's 2002 Annual Report Canada In 2002, sales growth in Canada was 10% with total sales of $570 million. AstraZeneca ranks number four in Canada with a 7% market share. The product portfolio performed well. Symbicort was successfully launched and is rapidly gaining market share. Nexium showed strong performance since its 2001 launch and continued to build market share. Two product franchises, Atacand and Seroquel, performed very well over the previous year with increases of 47% and 58% respectively. The Oncology group had another successful year with sales growth of 13%, driven largely by Zoladex and Casodex. AstraZeneca ranks number one in Canada in oncology with a 22% market share.